NeoplasmsNCT07206914
Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital
An observational study of Neoplasms and Oncology Service, run by Centre Hospitalier de Saint-Denis at 1 site in France.
Trial summary
This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Neoplasms, Oncology Service, Health Services Accessibility
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- 15 Oct 2025to 15 Apr 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Study participants will be selected from the population of patients treated for cancer in the oncology department of Delafontaine Hospital, located in Seine-Saint-Denis (93), France. This population includes adult patients receiving chemotherapy, radiotherapy, targeted therapies, immunotherapy, or supportive care as part of their cancer management. Since Delafontaine Hospital is a public hospital in a densely populated and socioeconomically diverse area of the Paris region, the patient population is expected to reflect a wide range of social, cultural, and economic backgrounds, including a high proportion of individuals from immigrant communities. This diversity provides a valuable context for studying inequalities in geographic accessibility to oncology care.
Who may be able to join
- Adult patients treated for cancer in the oncology department of Delafontaine Hospital since January 1, 2020.
Who cannot join
- Patients whose cancer treatment in the oncology department was completed before 2020.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Centre Hospitalier de Saint-Denis
Saint-Denis, France
Gaëtan Des Guetz, 0142356208, coordination.rechercheclinique@ghtpdfr.fr
About this study
This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. The goal is to better understand inequalities in access to care and to improve patient support in the future.
- Conditions
- Neoplasms, Oncology Service, Health Services Accessibility, Health Inequalities, Residence Characteristics, Transportation of Patients
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Median travel time (minutes) from the patient's place of residence (IRIS centroid) to Delafontaine Hospital by the patient's usual mode of transport for oncology appointments.
Measured: Assessed up to 5 years after first inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Oct 2025
- Study start15 Oct 2025 (estimated)
- Primary completion15 Apr 2026 (estimated)
- Study completion15 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier de Saint-Denis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07206914
- Sponsor's protocol ID
- 0116_ONCOLOGIE
- Status last verified
- Sep 2025
- First submitted
- 26 Sep 2025
- Last updated
- 3 Oct 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital
- ClinicalTrials.gov ID
- NCT07206914
- Acronym / sponsor ID
- 0116_ONCOLOGIE
- Conditions
- Neoplasms, Oncology Service, Health Services Accessibility, Health Inequalities, Residence Characteristics, Transportation of Patients
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Centre Hospitalier de Saint-DenisUniversity, hospital or other
- Study start
- 15 Oct 2025 (estimated)
- Primary completion
- 15 Apr 2026 (estimated)
- Study completion
- 15 Apr 2026 (estimated)
- First posted
- 3 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. The goal is to better understand inequalities in access to care and to improve patient support in the future.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Study participants will be selected from the population of patients treated for cancer in the oncology department of Delafontaine Hospital, located in Seine-Saint-Denis (93), France. This population includes adult patients receiving chemotherapy, radiotherapy, targeted therapies, immunotherapy, or supportive care as part of their cancer management. Since Delafontaine Hospital is a public hospital in a densely populated and socioeconomically diverse area of the Paris region, the patient population is expected to reflect a wide range of social, cultural, and economic backgrounds, including a high proportion of individuals from immigrant communities. This diversity provides a valuable context for studying inequalities in geographic accessibility to oncology care.
Key inclusion criteria (1 listed)
- Adult patients treated for cancer in the oncology department of Delafontaine Hospital since January 1, 2020.
Key exclusion criteria (1 listed)
- Patients whose cancer treatment in the oncology department was completed before 2020.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Median travel time (minutes) from the patient's place of residence (IRIS centroid) to Delafontaine Hospital by the patient's usual mode of transport for oncology appointments.
Time frame: Assessed up to 5 years after first inclusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Oct 2025.
Related trials for Neoplasms
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Centre Hospitalier de Saint-Denis
Saint-Denis, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neoplasms and Oncology Service, run by Centre Hospitalier de Saint-Denis at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Median travel time (minutes) from the patient's place of residence (IRIS centroid) to Delafontaine Hospital by the patient's usual mode of transport for oncology appointments. (time frame: Assessed up to 5 years after first inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2025.